News Agency
Men's Weekly

Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' 'European Heart Journal'

  • Written by PR Newswire
Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' 'European Heart Journal'

SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'.

R&D-oriented pharmaceutical company, Hanmi Pharmaceutical's...

Read more: Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed...

How Labour Hire Supports Sydney and Gold Coast Businesses

Labour hire has transformed from a simple stopgap measure into one of the most strategically valuable workforce solutions for businesses right across Sydney and the Gold Coast. As various industries grow, adapt to punishing seasonal demand, or suddenly find themselves... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion